By Ted Bosworth
Two new studies of drugs already licensed for cancer—one indicated for acute lymphoblastic leukemia (ALL) and one approved for both ALL and acute lymphoblastic lymphoma (LBL)—have yielded new clues into the optimal dosing schedules for the agents. A third trial, focusing on a bispecific T-cell engager (BiTE) therapy, yielded impressive early responses with a subcutaneous formulation. The data were presented at the 2021 annual meeting of the American Society of
JANUARY 18, 2022